REV3L and colon carcinoma: REV3 depletion also increases sensitivity and decreases mutagenesis induced by cisplatin in mouse B-cell lymphomas and lung cancer cells, human and mouse fibroblast cells, and human colon carcinoma cells[22,23,24,25].